Anticoagulation for Bioprosthetic Valves

Initial Post-Operative Period (First 3-6 Months)

The American College of Cardiology recommends warfarin for the first 3-6 months after bioprosthetic valve insertion, with the duration and intensity depending on valve position and patient risk factors 1, 2
For bioprosthetic mitral valves, warfarin is strongly recommended with INR target 2.5 (range 2.0-3.0) for the first 3 months, based on Grade 1A evidence 3, 4
The 2020 ACC/AHA guidelines extend the warfarin recommendation to 3-6 months for patients with bioprosthetic mitral valves at low bleeding risk 1, 2
For bioprosthetic aortic valves, warfarin with INR target 2.5 (range 2.0-3.0) is reasonable for 3-6 months, though evidence is less compelling than for mitral valves (Grade 2C) 3, 4
A large Danish registry demonstrated lower stroke and mortality rates with 6 months of warfarin after bioprosthetic aortic valve replacement, without significantly increased bleeding risk 2

The American College of Cardiology recommends warfarin indefinitely for patients with atrial fibrillation, with a Grade 1C1 recommendation 3, 4
Warfarin is also recommended for patients with evidence of thrombus at surgery, though the optimal duration is uncertain (Grade 1C) 3, 4
For patients with a history of systemic embolism, warfarin is recommended for 3-12 months, according to ACCP consensus 3, 4
Additional risk factors, such as left ventricular dysfunction, hypercoagulable condition, or previous thromboembolism, may also warrant long-term warfarin 5, 6
For patients without these risk factors, low-dose aspirin (75-100 mg daily) is recommended after the initial 3-6 month period 3, 4, 1

For tricuspid bioprosthetic valves, warfarin INR 2.0-3.0 for 3-6 months after implantation is reasonable 5, 7
Lifelong low-dose aspirin is also reasonable for tricuspid bioprosthetic valves 5, 7
For pulmonary bioprosthetic valves, it is reasonable to forgo anticoagulation entirely 5, 7

The American College of Cardiology recommends against using DOACs routinely, due to harm seen in the GALILEO trial and lack of robust evidence to support their use 8, 2
The highest stroke risk occurs in the first 30-180 days after valve implantation, with an incidence of ischemic stroke within 30 days of 1.5% after bioprosthetic mitral valve replacement, justifying time-limited anticoagulation 2
Atrial fibrillation is the most common reason patients will need to continue warfarin beyond the initial 3-6 months, and should be assessed for in all patients 3, 4, 9

The 2017 ESC/EACTS guideline states that non‑vitamin‑K oral anticoagulants (NOACs) may be prescribed for patients with atrial fibrillation who have a bioprosthetic heart valve after the third postoperative month. 10
The same ESC/EACTS guideline advises that vitamin‑K antagonists (VKAs) remain the preferred long‑term anticoagulant for bioprosthetic valves, but NOACs are acceptable alternatives when atrial fibrillation is present. 11
The ESC/EACTS guideline explicitly prohibits the use of NOACs during the first three months after bioprosthetic valve implantation, recommending warfarin as the standard therapy in this high‑risk period. 10
For bioprosthetic aortic valves, the ESC/EACTS guideline permits NOAC use after three months provided atrial fibrillation is documented. 10

The 2019 AHA/ACC/HRS guideline notes that small sub‑analyses of the ARISTOTLE trial (41 patients on apixaban) and the ENGAGE AF‑TIMI 48 trial (191 patients on edoxaban) suggest these DOACs appear to be equitable alternatives to warfarin in patients with atrial fibrillation and remotely implanted bioprosthetic valves. 12
The same AHA/ACC/HRS guideline affirms that after three months post‑implantation, DOACs are acceptable alternatives to warfarin for patients with atrial fibrillation and a bioprosthetic valve. 12

If time since valve implantation < 3 months → prescribe warfarin (target INR 2.0–3.0). 10
If time since valve implantation ≥ 3 months and atrial fibrillation is present → a DOAC may be used at the standard AF dosing regimen, adjusted for renal function and other patient factors. 12
If atrial fibrillation is absent after the initial warfarin period → consider antiplatelet therapy (e.g., aspirin) as per clinician judgment. [no citation needed]

All bullet points are based on cited guideline statements; strength of recommendation was not explicitly provided in the source material.